Illumina Stock News

Illumina (ILMN) surpasses expectations in the first quarter in a challenging global macroeconomic environment.

SAN DIEGO , May 3, 2024 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced that its executives will be speaking at the following investor conference: RBC 2024 Global Healthcare Conference o

Although the revenue and EPS for Illumina (ILMN) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics compare with Wall Street

Illumina reiterated its 2024 revenue forecast on Thursday, expecting continued weak demand from its customers such as medical research labs and hospitals.

Here is a sneak peek into how the five MedTech stocks, HOLX, ZBH, ILMN, TFX and BRKR, are expected to fare in their quarterly results slated to be released tomorrow.

Evaluate the expected performance of Illumina (ILMN) for the quarter ended March 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics f

Illumina (ILMN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

These undervalued stocks from the growth side of the Morningstar style box are among our analysts' favorites today. 00:00 Introduction 00: 31 Adobe ADBE 01:09 Illumina ILMN I'm Susan Dziubinski with M

The EU's executive Commission approved Illumina's plan to unwind its completed acquisition of cancer diagnostic test maker Grail , it said in a statement on Friday.

Illumina said on Tuesday Chief Financial Officer Joydeep Goswami would leave the gene sequencing company and would be succeeded by former Summit Therapeutics' executive Ankur Dhingra.

The stock market has been in a solid rally since the third quarter of 2023, pushing significant indices to new highs. That upward trajectory also raised company valuations for many stocks, putting inv

SAN DIEGO , April 4, 2024 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) announced today that it will issue results for the first quarter 2024 following the close of market on Thursday, May 2, 2024. 

Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.

The gene-sequencing specialist might be able to complete a big-ticket asset buy after all. Its attempt to purchase Grail for $8 billion had been blocked by a European Union regulator.

Europe's top court should back U.S. gene sequencing company Illumina's appeal against the EU antitrust regulators' review of its $7.1 billion bid for cancer test maker Grail , an adviser to the court